文献速递胸部肿瘤

不可切除EGFR突变非小细胞肺癌同步放化疗后巩固奥希替尼对比度伐利尤单抗对比观察的多中心回顾性队列研究

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
PubMed 文献 · J Thorac Oncol · 2024-01-24

这项多机构国际回顾性分析纳入24家机构2015至2022年间136例III期EGFR突变不可切除NSCLC患者,比较同步放化疗后巩固奥希替尼、度伐利尤单抗或观察的结局。中位随访46个月,校正淋巴结状态、IIIA/B/C分期和年龄后,奥希替尼组24个月真实世界无进展生存率显著长于度伐利尤单抗组或观察组(奥希替尼86% vs 度伐利尤单抗30% vs 观察27%,两项比较p均<0.001),度伐利尤单抗组与观察组间无差异,三组总生存未检出显著差异,可能因随访有限。

要点

  • III期EGFR突变NSCLC同步放化疗后巩固奥希替尼的24个月rwPFS为86%,度伐利尤单抗30%、观察27%(两项比较p均<0.001)。
  • 度伐利尤单抗组与观察组的rwPFS无差异,三组总生存未检出显著差异,可能因随访有限。
  • 奥希替尼组任何级别trAE 52%(≥3级2例[6.1%]),度伐利尤单抗组48%(≥3级10例[18%])。

核心结论

  • 本研究提示,在携带致敏EGFR突变的III期不可切除NSCLC患者中,巩固奥希替尼与度伐利尤单抗或观察相比与显著更长的rwPFS相关。
  • 巩固奥希替尼未观察到非预期安全性信号。

研究设计与样本

  • 多机构国际回顾性分析,覆盖24家机构,纳入2015至2022年间接受同步放化疗后巩固奥希替尼、度伐利尤单抗或观察的III期EGFR突变NSCLC患者。
  • 共136例接受根治性同步放化疗的III期EGFR突变NSCLC患者,其中56例接受巩固度伐利尤单抗、33例接受巩固奥希替尼、47例仅观察。
  • 采用Kaplan-Meier法估计真实世界无进展生存(rwPFS,主要终点)和总生存(次要终点),采用多变量Cox回归分析。
  • 巩固治疗期间治疗相关不良事件(trAE)采用不良事件通用术语标准5.0版定义。

主要发现

  • 三队列基线特征相似;整个队列中位随访46个月,奥希替尼治疗中位持续时间未达到(四分位距:未达到-未达到),度伐利尤单抗为5.5个月(四分位距:2.4-10.8)。
  • 校正淋巴结状态、IIIA/B/C分期和年龄后,巩固奥希替尼组24个月rwPFS为86%,度伐利尤单抗组为30%,观察组为27%(两项比较p均<0.001)。
  • 度伐利尤单抗队列与观察队列之间rwPFS无差异。
  • 三队列总生存未检出显著差异,可能因随访有限。
  • 奥希替尼组任何级别trAE发生率为52%(≥3级2例[6.1%]),度伐利尤单抗组为48%(≥3级10例[18%])。

局限性

  • 原文自述总生存未检出显著差异可能因随访有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Durvalumab improves survival when used as consolidation therapy after chemoradiation (CRT) in patients with stage III NSCLC. The optimal consolidation therapy for patients with EGFR-mutant (EGFRmut) stage III NSCLC remains unknown. METHODS: In this multi-institutional, international retrospective analysis across 24 institutions, we evaluated outcomes in patients with stage III EGFRmut NSCLC treated with concurrent CRT followed by consolidation therapy with osimertinib, durvalumab, or observation between 2015 and 2022. Kaplan-Meier method was used to estimate real-world progression-free survival (rwPFS, primary end point) and overall survival (secondary end point). Treatment-related adverse events (trAEs) during consolidation treatment were defined using Common Terminology Criteria for Adverse Events version 5.0. Multivariable Cox regression analysis was used. RESULTS: Of 136 patients with stage III EGFRmut NSCLC treated with definitive concurrent CRT, 56 received consolidation durvalumab, 33 received consolidation osimertinib, and 47 was on observation alone. Baseline characteristics were similar across the three cohorts. With a median follow-up of 46 months for the entire cohort, the median duration of treatment was not reached (NR) for osimertinib (interquartile range: NR-NR) and was 5.5 (interquartile range: 2.4-10.8) months with durvalumab. After adjusting for nodal status, stage III A/B/C, and age, patients treated with consolidation osimertinib had significantly longer 24-month rwPFS compared to those treated with durvalumab or in the observation cohorts (osimertinib: 86%, durvalumab: 30%, observation: 27%, p < 0.001 for both comparisons). There was no difference in rwPFS between the durvalumab and the observation cohorts. No significant difference in overall survival across the three cohorts was detected, likely due to the limited follow-up. Any-grade trAE occurred in 52% (2 [6.1%] grade ≥3) and 48% (10 [18%] grade ≥3) of patients treated with osimertinib and durvalumab, respectively. Of 45 patients who progressed on consolidation durvalumab, 37 (82%) subsequently received EGFR tyrosine kinase inhibitors. Of these, 14 (38%) patients developed trAEs including five patients with pneumonitis (14%; 2 [5.4%] grade ≥3) and five patients with diarrhea (14%; 1 [2.7%] grade ≥3). CONCLUSIONS: This study suggests that among patients with stage III unresectable NSCLC with a sensitizing EGFR mutation, consolidation osimertinib was associated with a significantly longer rwPFS compared to durvalumab or observation. No unanticipated safety signals were observed with consolidation osimertinib.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Nassar AH, Kim SY, Aredo JV, et al. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. J Thorac Oncol. 2024. PMID: 38278303. doi:10.1016/j.jtho.2024.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。